News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

NicOx SA (COX.PA) To Re-Focus Naproxcinod On Duchenne Muscular Dystrophy


2/14/2014 9:08:50 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SOPHIA ANTIPOLIS, France, Feb. 14, 2014 (GLOBE NEWSWIRE) -- Nicox S.A. (NYSE Euronext Paris: COX) today announced its decision to re-focus naproxcinod development efforts. Nicox has granted an undisclosed financial partner the right to enter into a period of exclusive evaluation to assess the potential development of naproxcinod and of next generation nitric oxide (NO)- donors outside the ophthalmology area. The evaluation will be entirely funded by this partner and will be focused initially on Duchenne muscular dystrophy (DMD). Nicox has granted the undisclosed partner the exclusive right, should the results of the evaluation be satisfactory to the partner, to invest at the end of the evaluation period in naproxcinod and next generation NO-donors outside ophthalmology through an independent structure. Nicox will not pursue any other development activities or discussions with third parties related to naproxcinod.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

comments powered by Disqus
NicOx SA
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES